Caris Life Sciences, Inc. (CAI) fair value: what the stock is really worth
As of Nov 6, 2026: fair value (intrinsic value) of Caris Life Sciences, Inc. stock $6.99, price $25.23, that is 72.3% below the price, quality 60 out of 100. Rating: strongly overvalued. Calculated from audited financials with 13 of our 26 valuation models and 37 quality factors, updated daily.
69 individual criteria per stock, every one traceableSee the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year. As of Nov 6, 2026.
How to read this chart
17‑month range $14.55 – $39.30 · fair‑value band $4.66 – $11.10 · the $25.23 price screens above the $6.99 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). As of Nov 6, 2026.
Follow Caris Life Sciences, Inc. Common Stock in your weekly email
Every Wednesday you see whether Caris Life Sciences, Inc. Common Stock is on track or worth a review, plus price against fair value. Free, up to 3 stocks.
We send you a confirmation link. Unsubscribe with one click.
Caris Life Sciences, Inc., an artificial intelligence TechBio company, provides molecular profiling services in the United States and internationally. It develops and commercializes solutions to transform healthcare using molecular information, and artificial intelligence/machine learning algorithms.
Show moreShow less
The company's molecular intelligence product portfolio includes MI Profile Platform, a whole exome sequencing (WES)/ whole transcriptome sequencing (WTS) tissue-based molecular profiling solutions; Caris Assure Platform WES/WTS blood-based molecular profiling solutions; Precision Whole Genome Platform, a whole genome sequencing (WGS) blood- and tissue-based profiling solutions; and Caris Detect, a WGS-based multi-cancer early detection solution; Caris WGS MRD a WGS and digital droplet polymerase reaction-based minimal residual disease solution; and Caris ChromoSeq, a WGS and WTS based assay for therapy selection in hematological cancers.
It also offers pharma research and development services comprising laboratory delivery, strategic data, and research services to biopharmaceutical customers. The company provides its precision oncology solutions to customers, such as hospitals, institutions and patients.
The company was founded in 2008 and is headquartered in Irving, Texas.
Stock analysis
Caris Life Sciences, Inc. (CAI) currently trades at $25.23, while our model-based Fair Value estimate is $6.99, 72% below the price, so the stock looks overvalued today.
Show more
Valuation
Bull case: the Growth DCF group reads highest at a median of $8.00 per share, and 0 of the 13 models we run sit above the $25.23 price.
Bear case: the Asset-Based group reads lowest at $1.59, and 13 of the 13 models stay below the price. Data coverage for this calculation is medium.
Scenario range: $4.66 (bear) to $11.10 (bull), the price of $25.23 sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 60/100 (solid quality), in the Healthcare sector.
Mixed Growth: Revenue is growing, but margins or cash flow do not fully confirm the trend.
Caris Life Sciences, Inc. Common Stock reported revenue of $812M in FY2025 versus $294M in FY2020, a compound +22.5%/yr. Reported net income was −$538M in FY2025.
Key figures
Market cap $7.1B Mid · P/E ratio 15.2 · P/S ratio 7.44 · EPS (TTM) $1.66 · Net margin −66.2% · Return on equity 20.1% · Return on assets (EBIT) −37.4% (5-year average) · Operating margin 10.2%.
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 44 out of 100 (low confidence).
What moves the price
Analysts expect earnings well below the last reported figure (earnings in transition, for example expiring patents or contracts); a fair value that looks fair on trailing earnings may then be too optimistic.
The share trades about 30% below its 52-week high and 73% above its 52-week low, currently above its 200-day average.
For context, the median of 10 Healthcare peers we cover trades at 10% fair-value upside, at −72%, CAI screens richer than that median.
Fair Value models
Bear$4.66Fair Value $6.99Bull$11.10
Price $25.23 · Downside -72.3%
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above starts from their evidence-weighted blend, not from a single model. In cyclical trough or peak years, after dilution or a stock split it is adjusted afterwards, so it can sit above or below the models. Based on fiscal year 2025 figures (about 10 months old). Earnings retained since then ($1.42 per share) are deliberately not added.Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds.Coverage ⓘCoverage = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
In the last 6 months, 2 officers or directors bought shares worth $1.5M, most recently on May 15, 2026. Over the same period, 3 people sold shares worth $27.2M. Buying cluster
SaleJohn Russel DentonOfficer7,500 shares at $31.82$238,650Sep 22, 2026
SaleBrian J BrilleOfficer, Director400,000 shares at $30.33$12.1MSep 17, 2026
SaleDavid Baxley SpetzlerPresident597,212 shares at $24.84$14.8MSep 4, 2026
BuyJon HalbertDirector68,000 shares at $14.56$990,080May 15, 2026
BuyJeff L VacircaDirector31,050 shares at $16.15$501,458May 11, 2026
SaleLuke Thomas PowerOfficer62,250 shares at $26.57$1.7MDec 11, 202510b5-1 plan
Plus 17 other filings such as grants, option exercises or tax withholding. They are not market purchases or sales.
Sales are often planned (taxes, diversification, 10b5-1 plans). Purchases with their own money are seen as the stronger sign. For information only: not part of the quality score or Fair Value.
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.83/100
Revenue is growing, but margins or cash flow do not fully confirm the trend.
Revenue growth 1 year
+97.0%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+46.5%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+22.5%
Start year 2020 (pandemic). Over 10 years: +12.5% a year
Revenue growth 22 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+13.7%
’13
’14
’15
’16
’17
’18
’19
’20
’22
’23
’24
’25
Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.
31.3% (2019) → −62.4% (2024)
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2025 is a loss year, no rate is defined from a loss
not computed
Growth Forecast
A lot of optimism in the price
The price assumes more growth than the company has delivered so far and more than analysts expect.
What the price assumes ⓘThis turns our valuation around: instead of asking what the share is worth, it asks what growth the current price requires. It uses the cash the company keeps after all spending (free cash flow), the same discount rate as our models, five years of growth, then slowing evenly to 2 % a year by year ten. Compared with the analysts' sales forecasts extended to the same five years (at least three analysts, for context only, it does not enter the Fair Value): within 3 percentage points counts as "in line" (amber), below that little optimism (green), above that a lot of optimism (red).
+41.4%
Yearly growth needed for the next five years to justify today's price.
What forecasts expect ⓘAnalysts publish sales forecasts for the next two fiscal years. For the years after that, growth slows evenly to 2 % a year by year ten (2 % is the long-run rate our models use). Projected years are marked as such.
+18.1%
Yearly sales growth analysts expect, extended to five years.
After inflation (USA: IMF forecast 2.4% a year to 2030, 3.1% from 2016 to 2025) that is about +38.1% a year for the price and +15.4% for the forecasts.
News mood ⓘNews mood, the average tone of recent news (96 articles), rated against how stocks are usually covered. 🚀 Hype = unusually upbeat · 🙂 Positive = above average · 😐 Neutral = typical · 🙁 Negative = below average · 😨 Very negative = unusually downbeat. It reflects the tone of coverage, not our valuation.Positive
Recent news coverage is more positive than average.
AI conclusion: High gross margins stand out as the main strength, while persistent losses and negative returns signal limited evidence of a durable moat.
Main risk: Guardant Health and Foundation Medicine could capture more customers in liquid biopsy and comprehensive profiling with their FDA-approved tests and broader payer coverage, pressuring Caris' volumes and margins.
Bull case: Caris could leverage its large multi-omic dataset and AI tools to differentiate its enhanced liquid biopsy platform against rivals and secure broader regulatory clearances that support adoption.
Bear case: Intense competition from established players with approved tests combined with regulatory scrutiny and debt obligations could limit market share gains and strain resources for platform expansion.
Caris has launched an enhanced liquid biopsy that combines whole exome sequencing, whole transcriptome sequencing and whole-blood analysis from a single draw. This builds a more complete molecular profile to guide precision oncology. Our models currently see the stock as overvalued. Will the upgrade accelerate clinical adoption or struggle against entrenched testing methods?
Compare Caris Life Sciences, Inc. Common Stock with another stock
Price, fair value, quality and upside side by side.
Free, no sign-up
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Biotechnology · 558 stocks
Beats the industry median on 6/13 measures
A mixed picture versus its industry peers.
Valuation
Quality Score60 · Top 25%
Fair Value upside−72.3% · Below median
Profitability
Return on equity (12 months)20.1% · Top 25%
Return on assets−47.8% · Bottom 25%
Net margin (12 months)10.6% · Above median
Operating margin (12 months)10.2% · Above median
Growth and dividend
Revenue growth (quarter YoY)45.4% · Top 25%
Balance sheet
Debt / equity0.66× · Highest 25%
Valuation Multiplesvs Biotechnology median · lower = cheaper
For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.
Cite: Fair Value Calculator (2026). "Caris Life Sciences, Inc. Common Stock Fair Value". https://www.fairvalue-calculator.com/stock/CAI
Frequently asked questions
Is Caris Life Sciences, Inc. (CAI) overvalued or undervalued?
As of Nov 6, 2026, our model estimates a fair value of $6.99 versus a price of $25.23, about 72% lower (overvalued).
What is the fair value of CAI?
Our model-based fair value for Caris Life Sciences, Inc. is $6.99 (as of Nov 6, 2026), built from audited fundamentals. The current price: $25.23.
What is the quality score of CAI?
Caris Life Sciences, Inc. has a Quality Score of 60/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Caris Life Sciences, Inc. (CAI)?
Our model-based price target is the fair value of $6.99 (as of Nov 6, 2026) from 13 valuation models. Cautious scenario $4.66, optimistic scenario $11.10. It is a calculation from audited fundamentals, not an analyst target.
What is the Caris Life Sciences, Inc. Common Stock stock forecast for 2026?
Our models put fair value at $6.99, about 72% lower versus a price of $25.23 (overvalued). Cautious scenario $4.66, optimistic scenario $11.10. The calculation is refreshed regularly with new filings.
What is the revenue of Caris Life Sciences, Inc. (CAI)?
Caris Life Sciences, Inc. reported trailing-twelve-month revenue of about $990M (latest available figure, as of Nov 6, 2026).
What growth is priced into Caris Life Sciences, Inc. (CAI)?
For today's price to be fair in a discounted-cash-flow model, Caris Life Sciences, Inc. would have to grow free cash flow by +41.4 % per year for five years (discount rate 9.7 %, then slowing evenly to 2 % perpetual growth by year ten). Over the last 5 years revenue grew +22.5 % per year. As of Nov 6, 2026.
What discount rate (WACC) does the fair value of CAI use?
Our models discount Caris Life Sciences, Inc. at 9.7 %: a base by market capitalisation (mid), country premium for USA. The same rate applies in all 26 models.
What is a reverse DCF?
A reverse DCF turns the usual calculation around. Instead of deriving a value from assumptions, it takes today's price as given and asks: what free-cash-flow growth would a company have to deliver for exactly this price to be fair? The result is not a forecast but the expectation already priced in. For Caris Life Sciences, Inc. that is +41.4 % per year for five years, then slowing evenly to 2 % by year ten, using the same discount rate (9.7 %) and the same formula as our fair value.
How much growth has Caris Life Sciences, Inc. (CAI) delivered so far?
Over the past 5 years revenue at Caris Life Sciences, Inc. grew +22.5 % a year. The price currently implies free-cash-flow growth of +41.4 % per year. Comparing the two shows how much confidence is in the price: if it demands more than has been delivered, the business has to accelerate for the maths to work.
How fast is the sector of Caris Life Sciences, Inc. (CAI) growing?
The median revenue growth in the sector is +6.2 % a year. That is the yardstick for the growth priced into Caris Life Sciences, Inc. (+41.4 % per year): it shows whether the expectation is within the usual range or beyond it.
What is the free cash flow yield of Caris Life Sciences, Inc. (CAI)?
The free-cash-flow yield on the price is 0.94 %: that much free cash flow Caris Life Sciences, Inc. produces per unit of market value. When it exceeds the discount rate of our models (9.7 %), the business already earns more than its cost of capital demands, and the price needs little additional growth.
What is the intrinsic value of Caris Life Sciences, Inc. (CAI)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Caris Life Sciences, Inc. it is $6.99 per share (as of Nov 6, 2026), against a price of $25.23. It is the blended result of 13 valuation models in 6 families (DCF Models, Earnings-Based, Multiples, Asset-Based, Growth DCF, Economic Profit).
Is Caris Life Sciences, Inc. Common Stock stock overvalued or undervalued in 2026?
As of Nov 6, 2026, CAI trades above its calculated fair value: price $25.23, fair value $6.99, a gap of about −72% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of CAI?
No. The price is what the market pays today ($25.23); the fair value is what the company's own numbers justify ($6.99). For Caris Life Sciences, Inc. the two are $18.24 per share apart. That gap is exactly why we show both numbers side by side.
How much is Caris Life Sciences, Inc. Common Stock worth?
The market values Caris Life Sciences, Inc. at about $7.1B (market capitalisation, as of Nov 6, 2026). Per share that is $25.23; our models calculate a fair value of $6.99 per share.
What do the bullish and bearish scenarios say about CAI?
Our models span a range for Caris Life Sciences, Inc.: cautious scenario $4.66, base $6.99, optimistic $11.10 per share (as of Nov 6, 2026, price $25.23). The range comes from different growth and margin assumptions, not from analyst opinions.
What is the P/E ratio of CAI?
Caris Life Sciences, Inc. trades at a price-to-earnings ratio of 15.2 (as of Nov 6, 2026). A P/E on its own says little: it compares the price with ONE year of profit, while our fair value of $6.99 is built from several models across several years. Other multiples: P/B 12.4, P/S 7.2, EV/EBITDA 38.6.
How solid is the balance sheet of Caris Life Sciences, Inc. (CAI)?
Balance-sheet figures for Caris Life Sciences, Inc. (as of Nov 6, 2026): return on equity 20.1%, debt of 0.66 per unit of equity. They feed the Quality Score of 60/100, which measures business quality independently of the share price.
How far is CAI from its 52-week high?
Caris Life Sciences, Inc. trades at $25.23, about 30% below its 52-week high of $36.14 and 73% above the low of $14.55 (as of Nov 6, 2026). Distance from the high says nothing about value: that is what the fair value of $6.99 is for.
Which stocks are comparable to Caris Life Sciences, Inc. Common Stock?
From the same area (Healthcare) we also value Vertex Pharmaceuticals Incorporated, Regeneron Pharmaceuticals, Inc, CSL Limited, argenx SE, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Caris Life Sciences, Inc. Common Stock stock attractive at the current price?
The data as of Nov 6, 2026: price $25.23, calculated fair value $6.99 (−72%), Quality Score 60/100, from 13 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of CAI calculated?
We run Caris Life Sciences, Inc. through 13 models from 6 families: DCF Models, Earnings-Based, Multiples, Asset-Based, Growth DCF, Economic Profit. Every model gets the same audited fundamentals; the fair value of $6.99 builds on their evidence-weighted average, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 13.0% above its aggregate fair value. Caris Life Sciences, Inc. itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Caris Life Sciences, Inc. (CAI)?
The closing price on Nov 6, 2026 was $25.23. Our model-based fair value is $6.99, about 72% lower (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Caris Life Sciences, Inc. Common Stock right now?
The price sits above even our optimistic bull case ($11.10). The favourable scenario is already priced in. Solid but not exceptional quality (60/100) and above fair value, neither a clear bargain nor a standout compounder. A fairly wide model range ($4.66 to $11.10) leaves room in how you read the outcome.
Key figures of Caris Life Sciences, Inc.
How large is the market capitalisation of Caris Life Sciences, Inc. (CAI)?
The market capitalisation of Caris Life Sciences, Inc. is $7.1B. The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Caris Life Sciences, Inc. (CAI)?
The price-to-sales ratio of Caris Life Sciences, Inc. is 7.44 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Caris Life Sciences, Inc. (CAI)?
Earnings per share at Caris Life Sciences, Inc. are $1.66 (price ÷ EPS = P/E 15.2). Earnings per share over the last twelve months: total profit spread across every single share.
What is the net margin of Caris Life Sciences, Inc. (CAI)?
The net margin of Caris Life Sciences, Inc. is −66.2% (fiscal year 2025). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Caris Life Sciences, Inc. (CAI)?
The return on equity (ROE) of Caris Life Sciences, Inc. is 20.1% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Caris Life Sciences, Inc. (CAI)?
On an EBIT basis the return on assets of Caris Life Sciences, Inc. is −37.4% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Caris Life Sciences, Inc. (CAI)?
The operating margin of Caris Life Sciences, Inc. is 10.2% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Caris Life Sciences, Inc. (CAI)?
Revenue at Caris Life Sciences, Inc. is growing +45.4% versus a year earlier (3y avg +46.5%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How much net cash does Caris Life Sciences, Inc. (CAI) hold?
Caris Life Sciences, Inc. holds more cash than debt, $419M net (fiscal year 2025). The company holds more cash than debt, a safety cushion.
Free · no account needed
Watch Caris Life Sciences, Inc. Common Stock in the live analysis
One click puts Caris Life Sciences, Inc. Common Stock on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.
Some data
Nov 6, 2026